Skip to main content
AAN.com

Abstract

Objective

To determine whether the total small vessel disease (SVD) score adds information to the prediction of stroke outcome compared to validated predictors, we tested different predictive models of outcome in patients with stroke.

Methods

White matter hyperintensity, lacunes, perivascular spaces, microbleeds, and atrophy were quantified in 2 prospective datasets of 428 and 197 patients with first-ever stroke, using MRI collected 24 to 72 hours after stroke onset. Functional, cognitive, and psychological status were assessed at the 3- to 6-month follow-up. The predictive accuracy (in terms of calibration and discrimination) of age, baseline NIH Stroke Scale score (NIHSS), and infarct volume was quantified (model 1) on dataset 1, the total SVD score was added (model 2), and the improvement in predictive accuracy was evaluated. These 2 models were also developed in dataset 2 for replication. Finally, in model 3, the MRI features of cerebral SVD were included rather than the total SVD score.

Results

Model 1 showed excellent performance for discriminating poor vs good functional outcomes (area under the curve [AUC] 0.915), and fair performance for identifying cognitively impaired and depressed patients (AUCs 0.750 and 0.688, respectively). A higher SVD score was associated with a poorer outcome (odds ratio 1.30 [1.07–1.58], p = 0.0090 at best for functional outcome). However, adding the total SVD score (model 2) or individual MRI features (model 3) did not improve the prediction over model 1. Results for dataset 2 were similar.

Conclusions

Cerebral SVD was independently associated with functional, cognitive, and psychological outcomes, but had no clinically relevant added value to predict the individual outcomes of patients when compared to the usual predictors, such as age and baseline NIHSS.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: the GBD 2013 study. Neuroepidemiology 2015;45:161–176.
2.
Jampathong N, Laopaiboon M, Rattanakanokchai S, Pattanittum P. Prognostic models for complete recovery in ischemic stroke: a systematic review and meta-analysis. BMC Neurol 2018;18:26.
3.
Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013;12:483–497.
4.
Concha L. A macroscopic view of microstructure: using diffusion-weighted images to infer damage, repair, and plasticity of white matter. Neuroscience 2014;276:14–28.
5.
Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology 2014;83:1228–1234.
6.
Klarenbeek P, van Oostenbrugge RJ, Rouhl RP, Knottnerus IL, Staals J. Ambulatory blood pressure in patients with lacunar stroke: association with total MRI burden of cerebral small vessel disease. Stroke 2013;44:2995–2999.
7.
Arba F, Inzitari D, Ali M, et al. Small vessel disease and clinical outcomes after IV rt-PA treatment. Acta Neurol Scand 2017;136:72–77.
8.
Liang Y, Chen YK, Mok VC, et al. Cerebral small vessel disease burden is associated with poststroke depressive symptoms: a 15-month prospective study. Front Aging Neurosci 2018;10:46.
9.
Huijts M, Duits A, van Oostenbrugge RJ, Kroon AA, de Leeuw PW, Staals J. Accumulation of MRI markers of cerebral small vessel disease is associated with decreased cognitive function: a study in first-ever lacunar stroke and hypertensive patients. Front Aging Neurosci 2013;5:72.
10.
Molad J, Kliper E, Korczyn AD, et al. Only white matter hyperintensities predicts post-stroke cognitive performances among cerebral small vessel disease markers: results from the TABASCO study. J Alzheimers Dis 2017;56:1293–1299.
11.
Ryu WS, Woo SH, Schellingerhout D, et al. Stroke outcomes are worse with larger leukoaraiosis volumes. Brain 2017;140:158–170.
12.
Dufouil C, Godin O, Chalmers J, et al. Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke 2009;40:2219–2221.
13.
Makin SD, Turpin S, Dennis MS, Wardlaw JM. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. J Neurol Neurosurg Psychiatry 2013;84:893–900.
14.
Choi KH, Kim JH, Kang KW, et al. Impact of microbleeds on outcome following recanalization in patients with acute ischemic stroke. Stroke Epub 2018 Dec 7.
15.
Passiak BS, Liu D, Kresge HA, et al. Perivascular spaces contribute to cognition beyond other small vessel disease markers. Neurology 2019;92:e1309–e1321.
16.
Appleton JP, Woodhouse LJ, Adami A, et al. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke. Neurology 2020;94:e439–e452.
17.
Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004;159:882–890.
18.
Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I: development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 2012;98:683–690.
19.
Jickling GC, Chen C. Rating total cerebral small-vessel disease: does it add up? Neurology 2014;83:1224–1225.
20.
Munsch F, Sagnier S, Asselineau J, et al. Stroke location is an independent predictor of cognitive outcome. Stroke 2016;47:66–73.
21.
Bigourdan A, Munsch F, Coupe P, et al. Early fiber number ratio is a surrogate of corticospinal tract integrity and predicts motor recovery after stroke. Stroke 2016;47:1053–1059.
22.
Kuchcinski G, Munsch F, Lopes R, et al. Thalamic alterations remote to infarct appear as focal iron accumulation and impact clinical outcome. Brain 2017;140:1932–1946.
23.
Linck PA, Kuchcinski G, Munsch F, et al. Neurodegeneration of the substantia nigra after ipsilateral infarct: MRI R2* mapping and relationship to clinical outcome. Radiology 2019;291:438–448.
24.
Bournonville C, Henon H, Dondaine T, et al. Identification of a specific functional network altered in poststroke cognitive impairment. Neurology 2018;90:e1879–e1888.
25.
Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin Scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007;38:1091–1096.
26.
Pendlebury ST, Mariz J, Bull L, Mehta Z, Rothwell PM. MoCA, ACE-R, and MMSE versus the national Institute of neurological disorders and stroke-Canadian stroke network vascular cognitive impairment harmonization standards neuropsychological battery after TIA and stroke. Stroke 2012;43:464–469.
27.
Sagen U, Vik TG, Moum T, Morland T, Finset A, Dammen T. Screening for anxiety and depression after stroke: comparison of the hospital anxiety and depression scale and the Montgomery and Asberg Depression Rating Scale. J Psychosom Res 2009;67:325–332.
28.
3DSlicer. Available at: slicer.org. Accessed November 2020.
29.
Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–838.
30.
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351–356.
31.
Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. Cerebrovasc Dis 2015;39:224–231.
32.
Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165–174.
33.
volBrain. Available at: volbrain.upv.es. Accessed November 2020.
34.
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373–1379.
35.
Heuschmann PU, Wiedmann S, Wellwood I, et al. Three-month stroke outcome: the European Registers of Stroke (EROS) investigators. Neurology 2011;76:159–165.
36.
Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015;162:W1–W73.
37.
Royston P, Altman D. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Appl Stat 1994;43:429–467.
38.
Rubin D. Multiple Imputation for Nonresponse in Surveys. New York: J. Wiley & Sons; 1987.
39.
Eekhout I, van de Wiel MA, Heymans MW. Methods for significance testing of categorical covariates in logistic regression models after multiple imputation: power and applicability analysis. BMC Med Res Methodol 2017;17:129.
40.
Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 2009;9:57.
41.
Jiang W, Varma S, Simon R. Calculating confidence intervals for prediction error in microarray classification using resampling. Stat Appl Genet Mol Biol 2008;7:Article 8.
42.
Vogenberg FR. Predictive and prognostic models: implications for healthcare decision-making in a modern recession. Am Health Drug Benefits 2009;2:218–222.
43.
Young FB, Lees KR, Weir CJ. Improving trial power through use of prognosis-adjusted end points. Stroke 2005;36:597–601.
44.
Johnston KC, Wagner DP, Wang XQ, et al. Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome?. Stroke 2007;38:1820–1825.
45.
Lau KK, Li L, Schulz U, et al. Total small vessel disease score and risk of recurrent stroke: validation in 2 large cohorts. Neurology 2017;88:2260–2267.
46.
Arsava EM, Bayrlee A, Vangel M, et al. Severity of leukoaraiosis determines clinical phenotype after brain infarction. Neurology 2011;77:55–61.
47.
Konig IR, Ziegler A, Bluhmki E, et al. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke 2008;39:1821–1826.
48.
Onteddu SR, Goddeau RP, Jr., Minaeian A, Henninger N. Clinical impact of leukoaraiosis burden and chronological age on neurological deficit recovery and 90-day outcome after minor ischemic stroke. J Neurol Sci 2015;359:418–423.
49.
Song TJ, Kim J, Song D, et al. Total cerebral small-vessel disease score is associated with mortality during follow-up after acute ischemic stroke. J Clin Neurol 2017;13:187–195.
50.
Tang EY, Amiesimaka O, Harrison SL, et al. Longitudinal effect of stroke on cognition: a systematic review. J Am Heart Assoc 2018;7:e006443.

Information & Authors

Information

Published In

Neurology®
Volume 96Number 4January 26, 2021
Pages: e527-e537
PubMed: 33184231

Publication History

Received: February 13, 2020
Accepted: September 11, 2020
Published online: November 12, 2020
Published in print: January 26, 2021

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

The study was supported by public grants from the French Agence Nationale de la Recherche within the context of the Investments for the Future Program, referenced ANR-10-LABX-57, and named TRAIL (Translational Research and Advanced Imaging Laboratory). The development cohort was funded by a public grant from the French government (PHRC [Programme Hospitalier de Recherche Clinique Inter-régional]) funded in 2012. The validation cohort was funded by the Hauts-de-France Regional Council, the Coeur et Artères foundation, and the French Ministry of Health. The authors thank the In-vivo Imaging and Functions core facility (ci2c.fr) for the MRI acquisitions of Strokdem database.

Authors

Affiliations & Disclosures

Juliette Coutureau, MD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Julien Asselineau, MSc
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
Participation in numerous scientific committees sponsored by my employer.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Paul Perez, MD, PhD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
(2) numerous scientific advisory boards of academic research clinical studies sponsored by CHU de Bordeaux (Bordeaux University Hospital, France). I was an employee of CHU de Bordeaux until 1stMay 2020
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Gregory Kuchcinski, MD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sharmila Sagnier, MD, PhD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Pauline Renou, MD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Fanny Munsch, PhD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Hilde Henon, MD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Regis Bordet, MD, PhD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
PI of a clinical study sponsored by Theranexus
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
a collaborative article on pharmacology of MS, revue neurologique, elsevier, granted by Novartis
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Grant of french Health ministery and Economy Ministery Grant from regional council
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Vincent Dousset, MD, PhD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Igor Sibon, MD, PhD
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
Participation to scientific advisory boards for the Following pharmaceutical companies: Servier, Medtronic and Boheringer-Ingelheim
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Associate editor of the Revue Neurologique (French) since 2017
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Thomas Tourdias, MD, PhD https://orcid.org/0000-0002-7151-6325
From the Neuroimagerie Diagnostique et Thérapeutique (J.C., V.D., T.T.), Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (J.A., P.P.), and Unité Neurovasculaire (S.S., P.R., I.S.), CHU de Bordeaux; Université de Bordeaux (J.C., S.S., V.D., I.S., T.T.); Département de Neuroradiologie (G.K., R.L.) and Unité Neurovasculaire (H.H.), CHU de Lille; Université de Lille (G.K., R.L., H.H., R.B.); INSERM U1171 (G.K., R.L., H.H., R.B.), Troubles Cognitifs Dégénératifs et Vasculaires, Lille; UMR 5287 (S.S., I.S.), CNRS, Neuroimagerie et Cognition, Bordeaux, France; Division of MRI Research (F.M.), Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and INSERM (V.D., T.T.), U1215, Neurocentre Magendie, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Grants from the French Agence Nationale de la Recherche within the context of the Investments for the Future program referenced ANR-10-LABX-57 named TRAIL and ANR-10-LABX-43 named BRAIN.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Grants from ARSEP foundation “Fondation pour l'aide a la recherche sur la sclérose en plaques”.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Tourdias [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Location-weighted versus Volume-weighted Mismatch at MRI for Response to Mechanical Thrombectomy in Acute Stroke, Radiology, 306, 2, (2023).https://doi.org/10.1148/radiol.220080
    Crossref
  2. Small vessel disease burden predicts functional outcomes in patients with acute ischemic stroke using machine learning, CNS Neuroscience & Therapeutics, 29, 4, (1024-1033), (2023).https://doi.org/10.1111/cns.14071
    Crossref
  3. The Clinical Utility of Leukoaraiosis as a Prognostic Indicator in Ischemic Stroke Patients, Neurology International, 14, 4, (952-980), (2022).https://doi.org/10.3390/neurolint14040076
    Crossref
  4. Predictors of post-stroke cognitive impairment using acute structural MRI neuroimaging: A systematic review and meta-analysis, International Journal of Stroke, 18, 5, (543-554), (2022).https://doi.org/10.1177/17474930221120349
    Crossref
  5. Subclinical Vascular Brain Lesions in Young Adults With Acute Ischemic Stroke, Stroke, 53, 4, (1190-1198), (2022).https://doi.org/10.1161/STROKEAHA.121.036038
    Crossref
  6. Chronic cerebral infarctions and white matter lesions link to long‐term survival after a first ischemic event: A cohort study, Journal of Neuroimaging, 32, 6, (1134-1141), (2022).https://doi.org/10.1111/jon.13033
    Crossref
  7. Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study, Alzheimer's & Dementia, 19, 4, (1152-1163), (2022).https://doi.org/10.1002/alz.12744
    Crossref
  8. Pathogeneses and Imaging Features of Cerebral White Matter Lesions of Vascular Origins, Aging and disease, 12, 8, (2031), (2021).https://doi.org/10.14336/AD.2021.0414
    Crossref
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share